CRA (Celera Corporatio)
All Pro Portfolios with CRA
All Do-It-Yourself Portfolios with CRA
- Total Do-It-Yourself Portfolios with CRA:
- keith Portfolio 2
- jack alter Portfolio 1
- Top Stem Cell Stocks
- SAM1933 Portfolio 1
- SUPRATRADE HOT WEDNESDAY EVENING "FAILING DOWN"
- rpm 1
- BENITRANS LIV
- yewed Portfolio 1
- Portfolio x1
- joekaro53 Portfolio 1
- Stockerblog.com Largest Stem Cell Stocks
- PART 1 JPMorgan 26th Annual Healthcare Conf 1/7/08..1st Day Reporting Companies..Nymph Take
- PART 6 JPMorgan 27th Annual Healthcare Conf 1/14/09..3rd Day Reporting Companies..Nymph Take
- Cramer's Take on Top Searched Stocks from 2-20-09
- show more
- 28
- TM StarSecurities House Acct
- kevin depew Portfolio 1
- Stockerblog.com Stem Cell Stocks
- BILLYT Portfolio 1
- SUPRATRADE NIGHT FEVER
- SUPRATRADE 0106071657
- SUPRATRADE 0706071737-7foryou
- my blizzard
- SUPRATRADE RED PORTFOLIO opp.123456
- jsandresen1 Portfolio 1
- bigsurmacn Portfolio 1
- Baby Teeth, Stem Cells, and Stocks
- handson
- Immediacy
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- Fannie + Goldman + US ...
- show more
- 02/11/09
Why I Love This Stock |
|
By:sarah z |
Date:02 20 09 |
From a recent Mad Money show:"I still like diagnostics. I know it's been hammered but I'm not backing away. I like Becton Dickinson (BDX), CR Bard (BCR) and Baxter International (BAX)." |
|
Not yet rated
Rate now:
|
|
Date:12 30 08 |
|
3 |
|
Not yet rated
Rate now:
|
|
By:stockerblog |
Date:06 18 08 |
P/E of 92, and a PEG of 42.8. |
|
Not yet rated
Rate now:
|
|
By:stockerblog |
Date:09 30 07 |
forward P/E of 156.22, P/S is 24. |
|
Not yet rated
Rate now:
|
|
By:rpm |
Date:05 17 07 |
Low Price/Book Ratio, Leader in Genomic Applications |
|
Not yet rated
Rate now:
|
|
Date:04 10 07 |
|
Biotech |
|
Not yet rated
Rate now:
|
|
By:Pam |
Date:02 24 07 |
Celera Group (CRA) This NYSE company, founded in 1937, is involved in the discovery and validation of new diagnostic markers, using proprietary genomics and proteomics discovery platforms and diagnostic products based on those markers. They collaborate with Abbott Laboratories, Genentech, General Electric and Merck. Negative earnings, P/S is 24. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Upgraded by Piper Jaffray from Market Perform to Outperform |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |
